Head of European Market Access – Oncology (Solid Tumors)

About the role

Summit Therapeutics, a biopharmaceutical oncology company with phase 3 studies in non-small cell lung cancer, colorectal cancer and bladder/urothelial cancer, is looking for a Head of European Market Access to lead pricing, reimbursement, health technology assessment and patient access strategies across Europe. The role can be based in Zug, Switzerland, Dublin, Ireland or Oxford, UK.

Key responsibilities

• Develop and execute an integrated European market access strategy for oncology products, covering EU5 and other key markets, and act as the European subject matter expert for senior leadership.
• Lead pricing and reimbursement strategies, including launch sequencing, price corridors, international reference pricing and lifecycle management, and country-specific HTA submissions.
• Work with clinical development, medical affairs, regulatory and HEOR teams to integrate payer requirements into trials, and support indirect treatment comparisons, health economic models and real-world evidence.
• Prepare launch plans, pricing scenarios and access milestones, and monitor reimbursement decisions and competitor launches.
• Engage payers, HTA bodies and policy stakeholders, and represent the company in market access forums and industry associations.
• Partner with Global Pricing, US Market Access, Finance and Commercial teams to assess European pricing and reimbursement impacts on global net revenue, US MFN exposure and gross-to-net, and to support business development and licensing decisions.

Required profile

• Advanced degree in life sciences, pharmacy, medicine, health economics, public health, business or a related field; MBA, PharmD, PhD or MD preferred.
• Minimum 15+ years in pharma or biotech, with significant European market access, pricing, reimbursement or HTA responsibility.
• At least 5+ years of oncology market access experience, preferably in solid tumors, with proven results on innovative oncology products.
• Demonstrated experience in NSCLC, colorectal cancer and/or bladder/urothelial cancer, and direct experience with European launches, HTA submissions and pricing negotiations.
• Fluent English; additional European languages are an advantage.

Required skills

• Strong knowledge of EU5 healthcare systems, HTA processes and reimbursement pathways.
• Understanding of German AMNOG, French HAS/CEPS, UK NICE and Italian AIFA frameworks, and the EU HTA Regulation.
• Ability to turn clinical and health economic evidence into payer value propositions.
• Executive communication, negotiation, analytical and strategic planning skills.